Financial statements​

Download a PDF of the British Pharmacological Society’s financial statements for the year ended 31 December 2024.

The financial statements include the Financial Review, Statement of Financial Activities and Balance Sheet, together with the Notes to the Accounts. They show the overall financial performance of the Society and provide an analysis of the incoming resources and how they were applied in the performance of the Society’s objectives.  

Total Funds  

The financial performance reported is of the “Group”, which means the Society together with its two trading subsidiaries, BPS Assessment Limited and BPS Trading Services Limited.  

The total funds of the Group have increased by £641,867 and the resulting balance of total funds at 31 December 2024 amounted to £6,349,143.  

Income  

Income for the year totalled £4,742,376 which is a decrease of 11.3% from 2023, mostly attributable to the World Congress of Basical and Clinical Pharmacology which was held in 2023.   

Charitable activity income from journal publishing, which is ordinarily the Society's main income source, increased by 10.2% to £3,531,732. 

Member numbers increased by 8% to 4,613 and membership subscription income increased by 1.7% to £112,178. The increase is primarily attributable to increases in the numbers of Undergraduate and Early Career Members.

Scientific meetings income decreased by £1,070,154 to £317,712 due to WCP2023.

Income from educational activities came to £639,455 which is an increase of £109,425.

Investment income was £26,710 lower at £79,894.

Expenditure  

Expenditure on charitable activities totalled £4,300,927  which is a 23.1% decrease of £1,289,459 mostly attributable to WCP2023. 

Journal publishing costs increased by £212,761 to £1,712,490 reflecting increased publisher costs and Society support costs associated with publishing.

Educational activities expenditure was £1,264,544 - a 26.2% decrease of £449,910 over the previous year., reflecting the full year effect of the 2023 restructure.

Projects and awards at £181,368 was a 7.8% decrease of £15,296 over the previous year.  

Scientific meetings at £983,139 was a 51.5% decrease due to WCP2023.

Capital expenditure totalled £55,250 for a combination of enhancements to the prescribing assessment platform and initial development of the new website.

---

Previous: BPS Assessment Ltd
Go back to Annual Review 2024